Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Budesonide 9 mg vs Cortiment in Healthy Adults
NCT05519514Phase 1Completed
- Sponsor
- Abbott Laboratories
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of budesonide in ulcerative colitis (UC) (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Maximum plasma concentration and Area under the plasma concentration-time curve from time zero to the last measurable concentration. Started Jul 2021; status: completed.
02
Drugs
budesonide
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05519514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519514.